metabolic-research
Semaglutide
A long-acting GLP-1 receptor agonist with 94% human sequence homology, engineered for extended half-life through fatty acid acylation — the reference standard in incretin-based metabolic disease research.
For research and laboratory use only. Not for human consumption.
Subscribe & save: $181
Quantity
Add 1 more to save 10% per unit
Technical Data
Specifications
Technical Details
Bulk Pricing
Volume Pricing Guide
Quality Assurance
Certificate of Analysis
Certificate of Analysis
Research Overview
About Semaglutide
Semaglutide is a 31-amino-acid synthetic analogue of human glucagon-like peptide-1 (GLP-1) incorporating a C18 fatty diacid chain conjugated at lysine-34 via a mini-PEG linker. This structural modification confers albumin binding in plasma, resistance to DPP-4 enzymatic degradation, and a pharmacological half-life approaching seven days — enabling once-weekly dosing in clinical research protocols.
The compound acts through GLP-1 receptors distributed across the pancreatic islets, hypothalamic appetite centers, brainstem nuclei, and gastrointestinal tract. Receptor activation drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and centrally mediated appetite reduction. Clinical research programs have documented meaningful reductions in body weight attributable primarily to decreased caloric intake.
Beyond metabolic endpoints, emerging research is investigating GLP-1 receptor activation for potential cardioprotective and neuroprotective properties. ROEHN provides semaglutide at 99% HPLC-verified purity as a lyophilized powder, supporting the full spectrum of metabolic disease research from preclinical pharmacology through translational studies.
